# Pantera NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pantera

- Industry: Pharmaceuticals
- Headquarters: Belgium
- Website: www.pantera-life.com/
- Total disclosed funding: $70M
- Latest round: Series A (Sep 18, 2024)
- Investors on record: 7

## About

Founded in 2022 and based in Belgium, PanTera NV engages in the production of actinium-225 for targeted cancer therapy. In September 2024, Pantera NV raised EUR 93 million in series A funding led by new investor EQT Life Sciences, with participation from other new investors PMV, Paladin Capital Group, Korys, Eurazeo, Sck Cen, and Kurma Partners. The round was part of a larger EUR 133.95 million debt and series A funding. As of 2024, the company is headed by its CEO Sven Van Den Berghe.

PanTera focuses on the large-scale production of radiopharmaceuticals. It produces an Ac-225 which is an alpha-emitting radioisotope that helps fight cancers through Targeted Radio Therapy (TRT). This approach enables precise delivery of therapeutic radiation to tumors, minimizing damage to surrounding healthy tissue.  

The company plans to use the September 2024 funding to support the construction of a new production facility in Belgium and expand its business opportunities.

## Funding rounds

- Series A, Sep 18, 2024, $70M — Paladin Capital Group, EQT Life Sciences, Eurazeo, Korys, PMV, Kurma Partners, Sck Cen

## Investors

- Paladin Capital Group (https://capitalatlas.ai/funds/paladin-capital-group) — Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- Eurazeo (https://capitalatlas.ai/funds/eurazeo) — Series A
- Korys (https://capitalatlas.ai/funds/korys) — Series A
- PMV (https://capitalatlas.ai/funds/pmv) — Series A
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A
- Sck Cen — Series A